Xiliertinib - HUTCHMED
Alternative Names: HMPL-309; TheliatinibLatest Information Update: 28 Jun 2021
At a glance
- Originator Hutchison MediPharma
- Class Alkynes; Amides; Aniline compounds; Antineoplastics; Pyrroles; Pyrrolidines; Quinazolines; Small molecules
- Mechanism of Action Epidermal growth factor receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Solid tumours
- Discontinued Oesophageal cancer
Most Recent Events
- 09 Jun 2021 Hutchison MediPharma has been acquired and merged into HUTCHMED
- 28 Jan 2021 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease) in China (PO, Tablet)
- 06 Mar 2019 Chemical structure information added